Want to see SE:ICO full AI Analyst Report?
ICO Stock Chart & Stats
kr1.03
kr0.03(3.00%)
At close: 4:00 PM EDT
kr1.03
kr0.03(3.00%)
Day’s Range― - ―
52-Week Rangekr0.87 - kr2.79
Previous CloseN/A
Volume15.90K
Average Volume (3M)46.24K
Market Cap
kr87.89M
Enterprise Valuekr68.18
Total Cash (Recent Filing)kr37.12M
Total Debt (Recent Filing)kr4.32M
Price to Earnings (P/E)―
Beta-0.40
Next Earnings
Oct 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding74,800,380
10 Day Avg. Volume58,575
30 Day Avg. Volume46,237
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.37
Price to Sales (P/S)39.24
P/FCF Ratio-0.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.42
Revenue Forecast (FY)kr29.00M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthStrong recent top-line growth suggests increasing demand for Iconovo’s inhaled drug delivery platforms and development services. If partner adoption continues, this can expand the project base and improve operating leverage over the medium term.
Conservative Balance SheetLow leverage gives Iconovo greater financial flexibility than a heavily indebted development company. The balance sheet can provide capacity to fund platform development and withstand delays in partner projects, although losses still require careful capital management.
Proprietary Inhaler PlatformsA portfolio of proprietary inhaler platforms can support repeat partnerships across new and generic medicines, creating reusable development capabilities. Licensing, milestones, royalties and supply income also provide potential for scalable revenue beyond one-off services.
Bears Say
Deep Operating LossesSubstantial operating and net losses show that current revenue does not cover the company’s cost base. Continued losses can constrain investment, weaken negotiating flexibility with partners and increase dependence on external funding until projects mature.
Persistent Cash BurnMaterially negative operating and free cash flow means Iconovo is consuming cash while developing its pipeline. If partner milestones or commercialization are delayed, the company may need additional financing, creating dilution or execution risk.
Deteriorated Gross MarginsThe reversal from positive gross profit in 2024 to deeply negative gross profit indicates weak cost absorption and an unproven path to sustainable margins. Revenue growth alone may not translate into durable earnings without better project economics and cost control.
ICO FAQ
What was Iconovo AB’s price range in the past 12 months?
Iconovo AB lowest stock price was kr0.87 and its highest was kr2.79 in the past 12 months.
What is Iconovo AB’s market cap?
Iconovo AB’s market cap is kr87.89M.
When is Iconovo AB’s upcoming earnings report date?
Iconovo AB’s upcoming earnings report date is Oct 23, 2026 which is in 59 days.
How were Iconovo AB’s earnings last quarter?
Iconovo AB released its earnings results on Aug 20, 2026. The company reported -kr0.098 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Iconovo AB overvalued?
According to Wall Street analysts Iconovo AB’s price is currently Overvalued.
Does Iconovo AB pay dividends?
Iconovo AB does not currently pay dividends.
What is Iconovo AB’s EPS estimate?
Iconovo AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Iconovo AB have?
Iconovo AB has 74,800,380 shares outstanding.
What happened to Iconovo AB’s price movement after its last earnings report?
Iconovo AB reported an EPS of -kr0.098 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.282%.
Which hedge fund is a major shareholder of Iconovo AB?
Currently, no hedge funds are holding shares in SE:ICO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Iconovo AB
Based in Lund, Sweden, Iconovo AB (publ) focuses on the creation and licensing of advanced inhalation delivery systems. Their product portfolio encompasses a variety of dry powder inhalers, such as the versatile multi-dose ICOres, the capsule-driven ICOcap, the single-use disposable ICOone, and the pre-metered ICOpre. Beyond these standard devices, the company also designs custom inhalation solutions, primarily catering to generic pharmaceutical firms. Iconovo is involved in significant collaborative ventures, including a project with Immune System Regulation AB to develop an inhaled COVID-19 vaccine using their ICOone inhaler, and a partnership with Respiratorius AB (publ) to formulate an inhalation treatment for COPD. The company was established in 2013.